Jeremy S Abramson

59PUBLICATIONS
294CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRegenerative medicine (incl. stem cells)Applied statisticsLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (59)

|Oct 19, 2026
Prophylactic IFN-γ blockade drives axi-cel expansion without preventing refractory toxicities: caution against pre-emptive use.

|Oct 02, 2026
An Electronic Frailty Index Is Associated with Outcomes in Older Adults Receiving CAR-T Therapy.

|Aug 29, 2026
Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

|Jul 16, 2026
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.

|Jun 30, 2026
Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs.

|Jun 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Pageof 10

Frequent Collaborators

9 joint publications

Jacob D Soumerai

8 joint publications

Jeffrey Barnes

8 joint publications

Patrick Connor Johnson

6 joint publications

Manali Kamdar